SCHEMBL2007274

SCHEMBL2007274

OCCc1cscn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL243566 0.82
SCHEMBL907879 0.74 KDM4E (0.44)
SCHEMBL679244 0.71 SLC6A3 (0.38)
SCHEMBL736277 0.71
SCHEMBL8906103 0.71 SLC6A3 (0.37)
SCHEMBL10861601 0.71 HRH1 (0.44)
SCHEMBL3336038 0.70 GRM5 (0.39)
SCHEMBL7352434 0.70
SCHEMBL3512203 0.70
SCHEMBL7352430 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705293-A1 SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2026-03-11 EP disclosed
EP-4601635-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2025-08-20 EP disclosed
WO-2024229317-A1 SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-11-07 WO disclosed
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 US disclosed
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 WO disclosed
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2024-04-16 US disclosed
WO-2024067818-A1 CHIMERIC COMPOUND USED FOR TARGETED DEGRADATION OF BCL-2 PROTEIN, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF 江苏恒瑞医药股份有限公司 2024-04-04 WO disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
EP-1202990-A2 NEUROTROPHIC PYRROLIDINES AND PIPERIDINES, AND RELATED COMPOSITIONS CONTAINING THEM Ortho-McNeil Pharmaceutical, Inc. (US) 2002-05-08 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed
WO-2001004116-A2 NEUROTROPHIC PYRROLIDINES AND PIPERIDINES, AND RELATED COMPOSITIONS CONTAINING THEM ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-01-18 WO disclosed
CN-1020340-C 1-carbacephalosporin antibiotics LILLY CO ELI (US) 1993-04-21 CN disclosed
EP-0232623-B1 1-CARBACEPHALOSPORIN ANTIBIOTICS ELI LILLY AND COMPANY (US) 1993-03-17 EP disclosed
US-4892942-A 1-CARBA (DETHIA)CEPHALOSPORINS ELI LILLY AND COMPANY (US) 1990-01-09 US disclosed
US-4791106-A 1-Carbacephalosporin antibiotics ELI LILLY AND COMPANY (US) 1988-12-13 US disclosed
EP-0232623-A1 1-Carbacephalosporin antibiotics ELI LILLY AND COMPANY (US) 1987-08-19 EP disclosed
CN-86108961-A 1-CARBACEPHALOSPORIN ANTIBIOTICS 1987-08-05 CN disclosed
US-4033977-A ANTIINFLAMMATORY, ANTIDEPRESSANT AMERICAN HOME PRODUCTS CORPORATION (US) 1977-07-05 US disclosed